2014年2月
Preclinical Evaluation of MicroRNA-34b/c Delivery for Malignant Pleural Mesothelioma
Acta Medica Okayama
- 巻
- 68
- 号
- 1
- 開始ページ
- 23
- 終了ページ
- 26
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.18926/AMO/52140
- 出版者・発行元
- Okayama University Medical School
The microRNA-34s (miR-34s) have p53 response elements in their 5ʼ-flanking regions and demonstrate tumor-suppressive functions. In malignant pleural mesothelioma (MPM), we previously reported that expression of miR-34b and miR-34c (miR-34b/c) was frequently downregulated by methylation in MPM cell lines and primary tumors. The forced overexpression of miR-34b/c showed significant antitumor effects with the induction of apoptosis in MPM cells. In this study, we examined the in vivo antitumor effects of miR-34b/c using adenovirus vector on MPM. We subcutaneously transplanted NCI-H290, a human MPM cell line, into BALB/C mice and injected adenovirus vector expressing miR-34b/c, luciferase driven by the cytomegalovirus promoter (Ad-miR-34b/c or Ad-Luc), or PBS control into tumors over 5mm in diameter. A statistically significant growth inhibition of the tumor volume was observed in the Ad-miR-34b/c group from day 6 onward compared to the Ad-Luc group. The inhibitionrate of Ad-miR-34b/c, compared to the tumor volume treated with Ad-Luc, was 58.6% on day 10 and 54.7% on day13. Our results indicate that adenovirus-mediated miR-34b/c gene therapy could be useful for the clinical treatment of MPM.
- リンク情報
- ID情報
-
- DOI : 10.18926/AMO/52140
- ISSN : 0386-300X
- CiNii Articles ID : 120005372648
- CiNii Books ID : AA00508441